Bayer on Thursday provided additional data on late-stage studies of its rival drug to Astellas’ Veozah, which met all primary ...

GSK said Thursday it plans to divest its remaining 4.2% stake in the consumer health spinout, its fourth and final round of ...

Since taking the helm in 2023, Anderson has embarked on a radical departure from the traditional structure of large pharma ...

Bolstered by promising response data from its Phase II study, Amgen announced Thursday it got the FDA’s green light for its first-in-class bi-specific T-cell engager Imdelltra for extensive-stage ...

The European Medicines Agency on Friday recommended withdrawing approval for a drug used to prolong gestation due to the lack ...

Biogen and Ionis Pharmaceuticals on Thursday revealed early results from the Phase I/II ALSpire study, demonstrating that ...

The FDA on Thursday approved Amgen’s bispecific T-cell engager tarlatamab, which will now carry the brand name Imdelltra, for ...

A Senate health committee report published Wednesday forecasts spending on prescription drugs may hit $1 trillion a year in ...

Eli Lilly’s efsitora alfa, which is meant to be taken weekly instead of multiple times a day, demonstrated non-inferior A1C ...

Johnson & Johnson announced Thursday it is paying $850 million in cash, plus a potential milestone payment, for privately-held biotech Proteologix and its atopic dermatitis-focused bispecific antibody ...

Roche’s $2.7 billion acquisition of Carmot Therapeutics in December 2023 appears to be paying off as its investigational ...

Belgian biotech Galapagos is teaming with Blood Centers of America to help deploy its decentralized CAR-T therapy ...